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Dendritic cells (DCs) undergo maturation during virus infection and
thereby become potent stimulators of cell-mediated immunity.
HIV-1 replicates in immature DCs, but we now find that infection
is not accompanied by many components of maturation in either
infected cells or uninfected bystanders. The infected cultures do
not develop potent stimulating activity for the mixed leukocyte
reaction (MLR), and the DCs producing HIV-1 gag p24 do not
express CD83 and DC–lysosome-associated membrane protein
maturation markers. If different maturation stimuli are applied to
DCs infected with HIV-1, the infected cells selectively fail to mature.
When DCs from HIV-1-infected patients are infected and cultured
with autologous T cells, IL-10 was produced in 6 of 10 patients.
These DC–T cell cocultures could suppress another immune re-
sponse, the MLR. The regulation was partially IL-10-dependent and
correlated in extent with the level of IL-10 produced. Suppressor
cells only developed from infected patients, rather than healthy
controls, and the DCs had to be exposed to live virus rather than
HIV-1 gag peptides or protein. These results indicate that HIV-1-
infected DCs have two previously unrecognized means to evade
immune responses: maturation can be blocked reducing the effi-
cacy of antigen presentation from infected cells, and T cell-depen-
dent suppression can be induced.
Dendritic cells (DCs) mediate several protective responses toviral infection. DCs provide innate resistance, e.g., by
producing high levels of interferons, and DCs set the stage for
adaptive immunity by efficiently processing and presenting
antigens acquired through direct infection or capture of inactive
virions and dying virus infected cells (reviewed in ref. 1).
Importantly, as a result of infection, DCs can undergo an
extensive differentiation process called maturation, which is
initiated within the cell (2, 3) or after ligation of toll-like
receptors, e.g., TLR3 (4–6) and TLR9 (7–9), and IFN receptors
(5) at the cell surface or from within the endocytic system. This
maturation is critical, not only for DCs to become stimulators of
cell mediated immunity but also to avoid the induction of
tolerance, a function of different types of immature DCs (iDCs)
in the steady state (reviewed in refs. 10 and 11). Several changes
occur during DC maturation, many of which can be monitored
at the single cell level by fluorescent-activated cell sorter (FACS)
analyses, e.g., the up-regulation of antigen presenting MHC class
II and CD86 costimulatory molecules, and the de novo expres-
sion of cell surface CD83 and the lysosomal antigen DC–LAMP
(lysosome-associated membrane protein). Importantly, mature
DCs become potent stimulators for T cell-mediated immunity,
which is often assessed by stimulation of the mixed leukocyte
reaction (MLR) as a model. In trying to interface HIV-1
infection of DCs with these general principles of DC function
during virus infection, we began with prior evidence that iDCs
derived from blood and from skin preferentially replicate HIV-1
(12–16). Mature DCs, in contrast, when challenged with HIV-1,
do not replicate virus, in part because of a low level of surface
CCR5 expression (17–19) and also the result of reverse tran-
scription and postintegration blocks (20). We therefore have
studied the effects of HIV-1 infection on the maturation of
monocyte-derived iDCs. We will show that HIV-1 infection does
not induce many features of DC maturation and even retards it,
and that infected DCs interact with T cells from HIV-1-infected
patients to stimulate IL-10 production and immune suppression.
Materials and Methods
Patient Samples. Study subjects were normal healthy control
volunteers or HIV-1-infected patients. Eight HIV-1 patients
(Table 2, which is published as supporting information on the
PNAS web site) were receiving antiretroviral drugs and had been
clinically, immunologically, and virologically stable for at least
the year before study. Blood was obtained in Institutional
Review Board approved protocols.
DCs. CD14 monocytes were positively selected from blood
mononuclear cells by using CD14 magnetic beads (Miltenyi
Biotec, Auburn, CA). A total of 2  106 cells were plated in
six-well dishes (Falcon) in 3 ml of RPMI medium 1640 with 5%
human serum AB (Gemini Biological Products, Calabasas, CA),
recombinant granulocyte–macrophage colony-stimulating fac-
tor (100 unitsml, Leukine, Immunex), and rIL-4 (20 ngml, R
& D Systems). Cells were fed on days 2 and 4 with the same
concentration of cytokines. At day 6, most nonadherent cells
were immature HLA-DR, CD3, CD14, and CD83 DCs.
Mature DCs were induced by adding cytokines (IL-1, tumor
necrosis factor , and IL-6 at 10 ngml; R & D Systems) together
with PGE2 (1 gml; Sigma) or CD40L-expressing cells pro-
vided by J. Banchereau (Baylor Institute, Dallas).
Cell Lines. MAGI, a HeLa cell clone expressing CD4, CCR5, and
HIV-LTR- gal was obtained from National Institutes of Health
AIDS Research Reagent Program and maintained in
DMEM5% FCS with selection medium (0.2 mg/ml G4180.1
mg/ml hygromycin B1 g/ml puromycin).
Viruses and Infection of DCs. The Ba-L HIV-1 isolate was grown in
mitogen-stimulated PBMC and titered in MAGI cells to deter-
mine infectious units (IU). In general, 105 iDCs were pulsed with
300 pg of HIV Ba-L or 3,000 IU for 2 h at 37°C. 3-Azido-3-
deoxythymidine AZT, 1 M, National Institutes of Health AIDS
Reagent Program) was added 1 h before infection and main-
tained throughout infection. Alternatively, DCs were infected
with 250 hemagglutinin units per ml of live influenza A virus
strain Aichi68 (SPAFAS) in RPMI medium 1640. After 1 h, 5%
Abbreviations: DC, dendritic cell; iDC, immature DC; MLR, mixed leukocyte reaction; AZT,
3-azido-3-deoxythymidine; FACS, fluorescence-activated cell sorting; CFSE, 5,6-
carboxyfluorescein diacetate-succinimyl ester; ELISPOT, enzyme-linked immunospot; LPS,
lipopolysaccharide; LAMP, lysosome-associated membrane protein.
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human serum was added to block infection, and the cells cultured
an additional 2–3 days.
Detection of HIV-1 Reverse Transcripts and p24-Expressing Cells.
Infected cultures were lysed and PCR amplified to detect early
(RU5) and late (LTRgag) reverse transcripts (21). Globin
sequences were amplified in parallel to control for DNA input.
For FACS assays, infected DCs were fixed with 4% paraformal-
dehyde in PBS for 30 min on ice. Cells were permeabilized for
15 min in 0.1% saponin and double stained with FITC anti-HIV
gag p24 (clone KC 57, Coulter) or anti-influenza HA (C102,
Abcam, Cambridge, MA), and phycoerythrin (PE)-labeled an-
tibodies to CD3 (clone SK7, BD), CD14 (clone MP9, BD),
HLA-DR (clone 243, BD), DC-SIGNCD209 (clone 120507, R
& D Systems), CD86 (clone 2331, Pharmingen), or DC–LAMP
CD207 (clone 104.64, Immunotech, Luminy, France). Samples
were analyzed on a FACSort (Becton Dickinson) with
CELLQUEST software.
MLR. Immature or mature DCs were pretreated or not with AZT
(1 M) and infected with HIV-1. After 5 days, DCs were
cultured with 5,6-carboxyfluorescein diacetate-succinimyl ester
(CFSE)-labeled allogeneic T cells (ratio 1:10) from another
blood donor, and the MLR was assessed by CFSE dilution.
DC–T Cell Cocultures. Infected and uninfected, immature and
mature DCs were cultured with autologous T cells (2  105) from
healthy adults or HIV-1-infected donors in round-bottom mi-
crotest wells at ratio of 1:30 for 7 days. Alternatively, iDCs were
treated with a panel of 122 peptides spanning the entire length
of p55 gag (National Institutes of Health AIDS Reagent Pro-
gram) at 2 M final concentration, or recombinant gag protein
at 5 gml (Protein Science, Meriden, CT).
Cytokine Assays. IFN- and IL-10 secreting cells were quantified
by a 36-h enzyme-linked immunospot (ELISPOT) assay initiated
at day 0, upon mixing DCs and T cells, or after 7 days of
coculture. ELISA assays (R & D Systems) also were used to
quantify cytokine released into culture supernatants.
Transwell Cultures to Detect Immune Regulation. Mixtures of DCs
and T cells, obtained from HIV-1-infected donors and cultured
for 7 days, were tested as suppressors of MLR proliferation. The
MLR was induced by adding mature DCs to CFSE-labeled,
negatively selected, allogeneic CD4 T cells (using the Un-
touched CD4 T cell selection, Miltenyi Biotec) at ratio 1:10. A
total of 105 MLR cells were placed in the bottom of a 96-well
plate, whereas 5  104 cells obtained from the 7-day DCHIV
plus T cell coculture were placed in the top of the transwell
chamber (0.2 m, Nunc Roskilde). In some experiments, inhib-
itory anti-IL-10 and control nonreactive antibodies were added.
Results
HIV-1 Infects a Fraction of iDCs. iDCs were generated from CD14
blood monocytes by culture with rIL-4 and recombinant gran-
ulocyte-macrophage colony-stimulating factor for 6 days. HIV-1
was then added for 4–6 days. Productively infected cells were
identified by gag p24 staining in the FACS. To confirm that the
small p24 subset was DCs, we double stained for p24 and
lineage markers. The p24 cells were negative for CD3 (T cells),
CD14 (monocytes), and CD19 (B cells), but positive for DC
markers like HLA DR, CD11c, and DC-SIGN (Fig. 1a). Inter-
estingly, p24 DCs were MHC class II-low. Because cell surface
MHC II increases during maturation, this indicates preferential
infection of the least mature DCs. To prove that p24 staining was
not caused by added virions, we showed that AZT, a reverse
transcriptase inhibitor, blocked formation of p24 DCs (Fig. 1b).
Thus HIV-1 productively infects a small fraction of immature
monocyte-derived DCs.
HIV-1 Infection Does Not Mature DCs. To determine whether DCs
mature as a consequence of viral infection, we first emphasized
the DC–LAMP intracellular (lysosomal) marker for maturation
(22), identified in the same cells permeabilized to detect HIV-1
gag p24. If DCs were infected at the immature stage, the p24
cells remained DC–LAMP negative (Fig. 2a). To monitor sur-
Fig. 1. p24 expression by HIV-1-infected iDCs. (a) DCs were exposed to the
BaL isolate of HIV-1 for 2 h at 37°C. The FACS was used to monitor HIV infection
(FITC anti-gag p24) and surface antigens (y axis) 5 days later. (b) DCs were
infected without or with 1 M AZT and stained for CD11c and p24. One of six
similar experiments is shown.
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face markers of maturation in infected DCs, we used GFP
expressing HIV-1, engineered from the YU2 virus. Again,
maturation did not develop in the infected DCs or bystander
cells, whereas DCs matured with either cytokines or CD40
ligation (data not shown) up-regulated surface CD83 and HLA–
DR, and down regulated DC–SIGNCD209 (Fig. 2b). HIV-1 did
not replicate if added to DCs matured with cytokines (Fig. 2b),
CD40 ligation, or lipopolysaccharide (LPS) (data not shown),
consistent with prior reports (13, 23). In contrast to HIV-1,
influenza-virus-infected DCs did mature (Fig. 6, which is pub-
lished as supporting information on the PNAS web site) as
reported (24). As a functional assay for maturation, we added the
DCs to allogeneic T cells. iDCs, infected or not with HIV-1, were
equally weak MLR stimulators when compared to mature DCs
(Fig. 2c). These data indicate that HIV-1, in contrast to many
viruses, does not induce maturation of cultured monocyte-
derived DCs.
Maturation Stimuli Do Not Mature HIV-1-Infected DCs. We next
studied the effect of maturation stimuli on viral replication as a
function of time. iDCs were infected, and maturation cytokines
were added immediately or at 24-h intervals for up to 4 days. If
maturation stimuli were added at 0–48 h after infection, viral
replication was absent or very low, whereas at later time points
(72–96 h), significant numbers of full-length DNA transcripts
(Fig. 3a, right lane) and p24 cells (Fig. 3b) were noted relative
to the iDCs. Importantly, in eight experiments of this type, most
p24 DCs selectively remained DC–LAMP low (see Fig. 3b) in
the presence of different maturation stimuli, i.e., cytokines, LPS,
and CD40 ligation (Table 2). Therefore, infected DCs shut down
virus production if maturation stimuli are added shortly after
infection, or maturation of infected cells is selectively blocked
when the maturation stimulus is encountered later on.
HIV-1-Infected iDCs Induce IL-10 Production Upon Coculture with T
Cells. There is evidence that iDCs can induce IL-10-producing
regulatory cells (25). To evaluate this possibility, we infected
iDCs differentiated from HIV-1-infected patients and healthy
controls for 4 days and added these (or aliquots of uninfected
DCs) to autologous T cells (see Fig. 7, which is published as
supporting information on the PNAS web site, for experimental
design). When the DCs were HIV-1 infected, IL-10 and IFN-
were secreted by the DC–T cell cocultures, but DCs pulsed with
gag peptides rather than live virus stimulated mostly IFN-.
Infected cultures matured with cytokines elicited IFN- but not
IL-10 (Fig. 7 Right). To determine whether the observed re-
sponses were caused by direct infection of DCs, cells were
pretreated with AZT before HIV-1 infection. Treatment with
AZT inhibited cytokine secretion, indicating that direct infec-
Fig. 2. HIV-1 infection does not mature DCs. (a) iDC and DCs matured with
a cytokine mixture (mDC) were infected with BaL and stained for the DC–
LAMP maturation marker and p24 (intracellular staining). Similar findings
were made in eight experiments, including other maturation stimuli like LPS
and CD40 ligation (Table 2). (b) The iDCs and mDCs were infected with
Yu2-HIV-1GFP and analyzed for maturation markers (y axis) by FACS after 5
days (surface staining). (c) Allo MLR stimulation was monitored by CFSE
dilution by using CFSE-labeled T cells and the indicated DCs. The experiment
shown is representative of three or more experiments.
Fig. 3. Effect of maturation stimuli added to HIV-1-infected DCs. iDCs were
infected for 2 h. After washing, maturation cytokines (or LPS or CD40L, Table
2) were added immediately (time 0) or at the indicated times. Cells were
analyzed at 5 days by PCR for HIV-1 reverse transcripts (a) and FACS for
expression of p24 and the maturation marker DC–LAMP (b).









tion of DCs was primarily responsible for the cytokine secretion
(Fig. 7). T cells or DCs alone did not secrete cytokines (Fig. 7
Left), and the removal of natural killer cells did not alter the
outcome of IFN--secreting cells (not shown).
With this system, we tested cells from 10 consecutive HIV-1-
infected patients to look for IL-10 production immediately or
after 7 days of DC–T cell coculture. The antigen-presenting cells
in the ELISPOT assays for IFN- and IL-10 were the autologous
infected or uninfected DCs. Six of 10 patients showed a boost in
IL-10 after 7 days of coculture by ELISA (Table 3, which is
published as supporting information on the PNAS web site) or
ELISPOT (Fig. 4a) assays, whereas four of these six showed a
significant increase in IFN-- and IL-10-producing ELISPOTs
when measured during the first 36 h (day 0, Fig. 4a). Similar
results were obtained when five of these six patients were studied
for IL-10 production on a second occasion, but secreted trans-
forming growth factor  by ELISA was not detected (data not
shown). In contrast, cells from five healthy donors did not show
an HIV-1-dependent increase in IFN-- and IL-10-producing
cells by ELISA (data not shown) or ELISPOT assays (Fig. 4b).
Therefore, iDCs infected with HIV-1 induce IL-10 production
upon culture with T cells from HIV-1-infected patients.
Cocultures of Immature HIV-1-Infected DCs and T Cells Suppress
Allogeneic Responses. Next, we evaluated whether the T cells
generated during 7 days of coculture had regulatory properties.
Cells from 7-day cocultures of DC with or without HIV plus T
cells were added in transwells to a ‘‘third party’’ MLR to test
suppression by the release of soluble mediators. The MLR used
CFSE-labeled CD4 T cells and allogeneic mature DCs, both
from healthy noninfected donors, so that proliferation in the
MLR could be monitored by CFSE dilution. As shown in Fig. 5a
Right, T cells generated in the cocultures with immature HIV-
1-infected DCs suppressed proliferation in the MLR (fourth
row), whereas T cells derived from cultures of uninfected
immature or mature DCs did not suppress. In 10 patients studied
in this way (Table 3), the degree of suppression correlated
directly with the amount of IL-10 produced in parallel cultures
(Fig. 5a Left). Next, we observed that HIV-1 specifically induced
this regulation, because DCs pulsed with gag protein or gag
peptides did not elicit comparable responses (Fig. 5 b and c and
Table 1). Fig. 5 b Left and c Left also show that regulation did
not occur when immature HIV-1-infected DCs and T cells from
healthy donors were added to the MLR across a transwell filter.
In view of the correlation between MLR suppression and
amount of IL-10 produced, we tested blocking anti-IL-10 anti-
bodies. Blocking antibody, but not a control nonreactive anti-
body, reduced or totally reversed the suppressive activity in four
of six patients tested (Fig. 5d). Thus, immature virus-infected
DCs can generate IL-10-dependent suppression upon coculture
with autologous T cells.
Discussion
The consequences of virus infection on DC maturation depend
on the virus type. Herpes simplex virus, vaccinia virus, and
hepatitis C virus inhibit DC maturation (26–28), whereas infec-
tion with influenza (24) and dengue virus (29) leads to DC
maturation. Cytomegalovirus (30) and Epstein–Barr virus (31)
inhibit monocyte differentiation to iDCs. Ebola (32) and measles
virus (33, 34) also impair DC function. HIV-1 is already known
to have several mechanisms for immune evasion (reviewed in ref.
35), such as nef-dependent down modulation of MHC class I
expression, mutation of T cell epitopes, and a decrease in the
total number of DCs in blood. Nef HIV-1 and simian immuno-
deficiency virus can stimulate cultures of iDCs to produce
cytokines and chemokines (36). Here we have examined the
effects of HIV-1 on DCs derived from blood monocytes, em-
phasizing the fraction of cells that are productively infected in
the cultures. We have found two mechanisms that would further
allow HIV-1 to evade immunity. One is a block in many key
features of DC maturation, whereas the other is a T cell
inhibitory function that depends in part on the suppressive
cytokine IL-10 (reviewed in ref. 37).
Prior in vitro studies of the interaction of HIV-1 with DCs have
emphasized that these cells are a driving force for virus repli-
cation. A major pathway entails the capacity of DCs to sequester
and transmit HIV-1 to T cells with which the DCs are interacting.
This leads to enhanced viral replication in the T cells. In the case
of DCs derived from blood monocytes, the virus transmission
function involves a calcium-dependent lectin DC-SIGNCD209
Fig. 4. Detection and expansion of T cells secreting IFN- and IL-10. iDCs were generated from HIV-1-infected patients (a) or uninfected donors (b), infected
with HIV-1 for 4 days, and added to autologous T cells. IFN- and IL-10 production were assessed by ELISPOT immediately (day 0) or after 7 days of coculture.
Each symbol is a different patient. Statistical comparisons (P values at top) between uninfected and infected DCs were made by using Student’s t tests.
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that binds and internalizes HIV-1, thereby retaining the virus in
an infectious state for days before transmission to the T cell
(38–40). There is another pathway whereby DCs drive virus
replication: DCs themselves serve as a direct site for productive
infection. This has been observed with iDCs from three sources:
Langerhans cells (15, 16), monocyte-derived DCs (13), and
CD34-derived DCs (23). In these instances, only a small
fraction of the immature population is productively infected, as
indicated by the accumulation of HIV gag protein. Here, we have
studied the direct infection of immature monocyte-derived DCs,
and have uncovered additional consequences that may contrib-
ute to disease pathogenesis through immune evasion.
We began by evaluating HIV-1-infected, p24 iDCs. Matu-
ration by viruses is now realized to proceed by many pathways,
including stimulation of toll-like receptors, e.g., TLR9 by viral
DNA (7, 9, 41), TLR3 by double-stranded RNA (4–6), cyto-
plasmic protein kinase R (3), and IFN- receptors (5). However,
HIV-1 infection did not lead directly to maturation. All of the
infected cells expressing viral p24 did not acquire DC maturation
markers such as DC–LAMP and CD83 (Figs. 1 and 2). Likewise,
bystander uninfected DCs in the culture did not mature, as
assessed by cell surface remodeling and increased stimulation of
the MLR. Because mature DCs are the form that initiates T cell
immunity, both T helper 1 type CD4 helpers and CD8
cytotoxic T cells, infected DCs are likely to be compromised in
their capacity to directly initiate T cell immunity to newly
synthesized viral antigens.
We then identified an additional dimension to the lack of
maturation, which became apparent with the DC maturation
marker DC–LAMP. It is known that mature DC–LAMP DCs
are difficult to infect with HIV-1. This entails reductions at the
level of viral entry, for example, reduced expression of CCR5
chemokine coreceptor, the subsequent viral life cycle, and both
reverse transcription and DNA integration. We now find that
immature productively infected DCs (expressing HIV-1 gag
protein), if given different maturation stimuli 2 days after
infection (cytokines, LPS, CD40 ligand; Table 2), selectively fail
to express the maturation marker DC–LAMP, in contrast to the
noninfected DCs in the same cultures (Fig. 3B). Therefore,
infected monocyte-derived DCs seem to evade, at several levels,
the chance to mature and to become immunogenic for the viral
proteins that are being synthesized.
There are two potential consequences of these findings. First,
immunogenicity might be delayed if the infected DCs could not
mature and present viral antigens, although it would not be totally
blocked; this is because DCs should still be able to present viral
antigens from dying infected cells and inactive virions (42, 43).
However, such presentation would be delayed with respect to the
time required for the DCs to take up and process viral antigens, and
would allow other cells to replicate virus beforehand. A second
consequence is the possibility of more active immunosuppression
via infected iDCs. When we obtained DCs and T cells from
chronically infected donors (as opposed to healthy noninfected
donors, Fig. 5), and infected the DCs before addition to autologous
T cells, we found that the DC–T cell cocultures started to produce
IL-10, and furthermore, the cocultures could suppress another or
Fig. 5. Cocultures of infected immature DCs and T cells inhibit a MLR. DCs
from HIV-1-infected patients were infected or not with HIV-1 for 4 days and
then added to autologous T cells for 7 days. The indicated cells (Center) were
then placed in a transwell chamber. In the lower wells, an MLR was generated,
and proliferation was assessed by CFSE dilution. T CFSE indicates T cells
cultured without DCs. (A) (Left) Correlation between suppression of the MLR
and production of IL-10 (Table 2). (Right) Comparison between immature and
mature DCs to show the suppression by iDC HIV  T (fourth row). (b and c)
Comparison between iDCs infected with HIV-1 or pulsed with gag protein (b)
or peptides (c). (d) Neutralizing anti-IL-10 or isotype control antibody was
added at 10 gml, and healthy controls studied in parallel (Left).
Table 1. IL-10 (pgml) production by T cells cocultured with autologous DC
iDC  T iDC HIV  T iDC gag pep  T mDC  T mDC  HIV  T mDC gag pep  T
0 0 0 ND ND ND
0 130 0 ND ND ND
0 205 5 0 15 1
26 85 31 ND ND ND
157 163 ND 0 8 0
0 54 110 0 7 ND
0 280 0 ND ND ND
0 77 8 0 3 1
DCs were prepared from eight HIV-1 patients. Immature (iDC) and mature (mDC) DCs were infected with HIV-1
or pulsed with gag peptides (2 M) overnight. The different populations of DCs were cultured with autologous
T cells for 7 days. Supernatants were assessed for IL-10 released by ELISA. ND, not done because of insufficient cells.









‘‘third party’’ immune response, the MLR, by secreting soluble
factors including IL-10. We have been unable at this point to
determine whether the DCs andor T cells were the source of IL-10
in the cocultures, but we presume that the requirement for T cells
from infected donors signifies that these donors have generated a
Tr1 type of IL-10-producing suppressors (reviewed in ref. 44).
Interestingly, both IL-10 production and suppression were greatly
enhanced when the source of antigen was live virus vs. viral peptides
(Table 1). Possibly virus infection up-regulates ICOS-L on DCs,
because ICOS-L is implicated in the induction of IL-10 regulatory
T cells (45).
Our findings add to a considerable existing literature on IL-10
in HIV-1 infection. Elevated IL-10 production and serum levels
have been reported (46–50). Monocytes are a major cell type
producing IL-10 in blood cells from HIV-1-infected patients
(51), and IL-10 production can be induced by HIV-1 nef (52).
DCs have the potential to produce IL-10, but, interestingly,
HIV-1-infected DCs produce less of this cytokine (53). IL-10
up-regulates the expression of CCR5 on monocytes, leading to
more efficient HIV-1 infection (54). In view of these data, as well
as recent studies indicating that different types of iDCs can
induce T cell tolerance, e.g., by stimulating regulatory T cells (45,
55–57), we would speculate that HIV-1-infected iDCs are more
tolerogenic then immunogenic.
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